« Return to News | Drug Sponsors

Astellas to sell diabetes patents

Friday, July 1, 2011 10:13 AM

Japanese drug maker Astellas Pharma is selling its diabetes-related patents to a fund for $609 million, to then be invested in strategic initiatives, according to Reuters.

Royalty Pharma will own the patents and have the royalty rights relating to the use of dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes.

"The sale of this large, passive, non-core financial asset will free up capital for reinvestment in strategic initiatives," said Astella CEO Yoshihiko Hatanaka.

The company will use the funds to invest further in its core areas including urology, transplant-related medicines, infectious diseases and cancer treatments.

The patents belong to Prosidion, a unit of U.S. cancer specialist OSI Pharmaceuticals, which Astellas acquired last year. Astellas said the transaction will have a minimal impact on its earnings forecasts for the current financial year.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.